{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["osteosarcoma", "ursolic acid", "zoledronic acid"]], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "27916903", "DateCompleted": {"Year": "2017", "Month": "05", "Day": "15"}, "DateRevised": {"Year": "2023", "Month": "12", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "11", "Day": "30"}], "ELocationID": ["1640"], "Language": ["eng"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "21", "Issue": "12", "PubDate": {"Year": "2016", "Month": "Nov", "Day": "30"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy.", "Abstract": {"AbstractText": ["Ursolic acid (UA), a naturally occurring pentacyclic triterpene acid found in many medicinal herbs and edible plants, triggers apoptosis in several tumor cell lines but not in human bone cancer cells. Most recently, we have demonstrated that UA exposure reduces the viability of human osteosarcoma MG-63 cells through enhanced oxidative stress and apoptosis. Interestingly, an inhibitor of osteoclast-mediated bone resorption, zoledronic acid (ZOL), also a third-generation nitrogen-containing bisphosphonate, is effective in the treatment of bone metastases in patients with various solid tumors. In this present study, we found that UA combined with ZOL to significantly suppress cell viability, colony formation, and induce apoptosis in two lines of human osteosarcoma cells. The pre-treatment of the antioxidant had reversed the oxidative stress and cell viability inhibition in the combined treatment, indicating that oxidative stress is important in the combined anti-tumor effects. Moreover, we demonstrated that ZOL combined with UA significantly induced autophagy and co-administration of autophagy inhibitor reduces the growth inhibitory effect of combined treatment. Collectively, these data shed light on the pathways involved in the combined effects of ZOL and UA that might serve as a potential therapy against osteosarcoma."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Orthopedics & Sports Medicine Laboratory, Changhua Christian Hospital, Changhua 50006, Taiwan. 50560@cch.org.tw."}, {"Identifier": [], "Affiliation": "Department of Orthopedic Surgery, Changhua Christian Hospital, Changhua 50006, Taiwan. 50560@cch.org.tw."}, {"Identifier": [], "Affiliation": "Institute of Biomedical Sciences, National Chung Hsing University, 145 Xingda Rd., South Dist., Taichung 40227, Taiwan. 50560@cch.org.tw."}, {"Identifier": [], "Affiliation": "School of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. 50560@cch.org.tw."}], "LastName": "Wu", "ForeName": "Chia-Chieh", "Initials": "CC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Orthopedics & Sports Medicine Laboratory, Changhua Christian Hospital, Changhua 50006, Taiwan. 181064@cch.org.tw."}], "LastName": "Huang", "ForeName": "Yi-Fu", "Initials": "YF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Orthopedics & Sports Medicine Laboratory, Changhua Christian Hospital, Changhua 50006, Taiwan. 51114@cch.org.tw."}, {"Identifier": [], "Affiliation": "Department of Orthopedic Surgery, Changhua Christian Hospital, Changhua 50006, Taiwan. 51114@cch.org.tw."}], "LastName": "Hsieh", "ForeName": "Chen-Pu", "Initials": "CP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Biomedical Sciences, National Chung Hsing University, 145 Xingda Rd., South Dist., Taichung 40227, Taiwan. pjchueh@dragon.nchu.edu.tw."}, {"Identifier": [], "Affiliation": "Department of Biotechnology, Asia University, Taichung 41354, Taiwan. pjchueh@dragon.nchu.edu.tw."}, {"Identifier": [], "Affiliation": "Graduate Institute of Basic Medicine, China Medical University, Taichung 40402, Taiwan. pjchueh@dragon.nchu.edu.tw."}, {"Identifier": [], "Affiliation": "Department of Medical Research, China Medical University Hospital, Taichung 40402, Taiwan. pjchueh@dragon.nchu.edu.tw."}], "LastName": "Chueh", "ForeName": "Pin-Ju", "Initials": "PJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. 31560@cch.org.tw."}, {"Identifier": [], "Affiliation": "Transplant Medicine & Surgery Research Centre, Changhua Christian Hospital, Changhua 50006, Taiwan. 31560@cch.org.tw."}, {"Identifier": [], "Affiliation": "Department of Surgery, Changhua Christian Hospital, 135 Nansiao St., Changhua 50006, Taiwan. 31560@cch.org.tw."}], "LastName": "Chen", "ForeName": "Yao-Li", "Initials": "YL"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Diphosphonates"}, {"RegistryNumber": "0", "NameOfSubstance": "Imidazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Reactive Oxygen Species"}, {"RegistryNumber": "0", "NameOfSubstance": "Triterpenes"}, {"RegistryNumber": "6XC1PAD3KF", "NameOfSubstance": "Zoledronic Acid"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug effects"], "DescriptorName": "Autophagy"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Diphosphonates"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Imidazoles"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Osteosarcoma"}, {"QualifierName": [], "DescriptorName": "Oxidative Stress"}, {"QualifierName": ["metabolism"], "DescriptorName": "Reactive Oxygen Species"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Triterpenes"}, {"QualifierName": [], "DescriptorName": "Zoledronic Acid"}, {"QualifierName": [], "DescriptorName": "Ursolic Acid"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Broadhead M.L., Clark J.C., Myers D.E., Dass C.R., Choong P.F. The molecular pathogenesis of osteosarcoma: A review. Sarcoma. 2011;2011:959248. doi: 10.1155/2011/959248.", "ArticleIdList": ["10.1155/2011/959248", "PMC3087974", "21559216"]}, {"Citation": "Jaffe N. Osteosarcoma: Review of the past, impact on the future. The american experience. Cancer Treat. Res. 2009;152:239\u2013262.", "ArticleIdList": ["20213394"]}, {"Citation": "Li J.S., Wang W.J., Sun Y., Zhang Y.H., Zheng L. Ursolic acid inhibits the development of nonalcoholic fatty liver disease by attenuating endoplasmic reticulum stress. Food Funct. 2015;6:1643\u20131651. doi: 10.1039/C5FO00083A.", "ArticleIdList": ["10.1039/C5FO00083A", "25892149"]}, {"Citation": "Kim E.S., Moon A. Ursolic acid inhibits the invasive phenotype of snu-484 human gastric cancer cells. Oncol. Lett. 2015;9:897\u2013902. doi: 10.3892/ol.2014.2735.", "ArticleIdList": ["10.3892/ol.2014.2735", "PMC4301486", "25621065"]}, {"Citation": "Xiang L., Chi T., Tang Q., Yang X., Ou M., Chen X., Yu X., Chen J., Ho R.J., Shao J., et al. A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis. Oncotarget. 2015;6:9295\u20139312. doi: 10.18632/oncotarget.3261.", "ArticleIdList": ["10.18632/oncotarget.3261", "PMC4496218", "25823660"]}, {"Citation": "Zhang J., Wang W., Qian L., Zhang Q., Lai D., Qi C. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition. Oncol. Rep. 2015;34:2375\u20132384. doi: 10.3892/or.2015.4213.", "ArticleIdList": ["10.3892/or.2015.4213", "26323892"]}, {"Citation": "Kim J.H., Kim Y.H., Song G.Y., Kim D.E., Jeong Y.J., Liu K.H., Chung Y.H., Oh S. Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of beta-catenin degradation. Food Chem. Toxicol. 2014;67:87\u201395. doi: 10.1016/j.fct.2014.02.019.", "ArticleIdList": ["10.1016/j.fct.2014.02.019", "24566423"]}, {"Citation": "Saraswati S., Agrawal S.S., Alhaider A.A. Ursolic acid inhibits tumor angiogenesis and induces apoptosis through mitochondrial-dependent pathway in ehrlich ascites carcinoma tumor. Chem. Biol. Interact. 2013;206:153\u2013165. doi: 10.1016/j.cbi.2013.09.004.", "ArticleIdList": ["10.1016/j.cbi.2013.09.004", "24051192"]}, {"Citation": "Wu C.C., Cheng C.H., Lee Y.H., Chang I.L., Chen H.Y., Hsieh C.P., Chueh P.J. Ursolic acid triggers apoptosis in human osteosarcoma cells via caspase activation and the ERK1/2 MAPK pathway. J. Agric. Food Chem. 2016;64:4220\u20134226. doi: 10.1021/acs.jafc.6b00542.", "ArticleIdList": ["10.1021/acs.jafc.6b00542", "27171502"]}, {"Citation": "Clemons M.J., Dranitsaris G., Ooi W.S., Yogendran G., Sukovic T., Wong B.Y., Verma S., Pritchard K.I., Trudeau M., Cole D.E. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J. Clin. Oncol. 2006;24:4895\u20134900. doi: 10.1200/JCO.2006.05.9212.", "ArticleIdList": ["10.1200/JCO.2006.05.9212", "17001071"]}, {"Citation": "Kohno N., Aogi K., Minami H., Nakamura S., Asaga T., Iino Y., Watanabe T., Goessl C., Ohashi Y., Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J. Clin. Oncol. 2005;23:3314\u20133321. doi: 10.1200/JCO.2005.05.116.", "ArticleIdList": ["10.1200/JCO.2005.05.116", "15738536"]}, {"Citation": "Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M., Coleman R.E., Reitsma D.J., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J. 2001;7:377\u2013387.", "ArticleIdList": ["11693896"]}, {"Citation": "Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M.A., Coleman R.E., Reitsma D.J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735\u20131744. doi: 10.1002/cncr.11701.", "ArticleIdList": ["10.1002/cncr.11701", "14534891"]}, {"Citation": "Polascik T.J., Given R.W., Metzger C., Julian S.R., Vestal J.C., Karlin G.S., Barkley C.S., Bilhartz D.L., McWhorter L.T., Lacerna L.V. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 2005;66:1054\u20131059. doi: 10.1016/j.urology.2005.05.035.", "ArticleIdList": ["10.1016/j.urology.2005.05.035", "16286123"]}, {"Citation": "Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J.L., Vinholes J.J., Goas J.A., Chen B., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 2002;94:1458\u20131468. doi: 10.1093/jnci/94.19.1458.", "ArticleIdList": ["10.1093/jnci/94.19.1458", "12359855"]}, {"Citation": "Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J.L., Vinholes J.J., Goas J.A., Zheng M., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 2004;96:879\u2013882. doi: 10.1093/jnci/djh141.", "ArticleIdList": ["10.1093/jnci/djh141", "15173273"]}, {"Citation": "Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., Hirsh V., Krzakowski M., Pawlicki M., De Souza P., Zheng M., Urbanowitz G., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613\u20132621. doi: 10.1002/cncr.20308.", "ArticleIdList": ["10.1002/cncr.20308", "15197804"]}, {"Citation": "Chang J., Wang W., Zhang H., Hu Y., Yin Z. Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells. Oncol. Lett. 2012;4:299\u2013304.", "ArticleIdList": ["PMC3402760", "22844373"]}, {"Citation": "Ory B., Blanchard F., Battaglia S., Gouin F., Redini F., Heymann D. Zoledronic acid activates the DNA s-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-g translocation independently of p53 and retinoblastoma status. Mol. Pharmacol. 2007;71:333\u2013343. doi: 10.1124/mol.106.028837.", "ArticleIdList": ["10.1124/mol.106.028837", "17050806"]}, {"Citation": "Hirbe A.C., Roelofs A.J., Floyd D.H., Deng H., Becker S.N., Lanigan L.G., Apicelli A.J., Xu Z., Prior J.L., Eagleton M.C., et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 2009;44:908\u2013916. doi: 10.1016/j.bone.2009.01.010.", "ArticleIdList": ["10.1016/j.bone.2009.01.010", "PMC2782613", "19442620"]}, {"Citation": "Moriceau G., Ory B., Mitrofan L., Riganti C., Blanchard F., Brion R., Charrier C., Battaglia S., Pilet P., Denis M.G., et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (everolimus): Pivotal role of the prenylation process. Cancer Res. 2010;70:10329\u201310339. doi: 10.1158/0008-5472.CAN-10-0578.", "ArticleIdList": ["10.1158/0008-5472.CAN-10-0578", "PMC3097388", "20971812"]}, {"Citation": "Dass C.R., Choong P.F. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther. 2007;6:3263\u20133270. doi: 10.1158/1535-7163.MCT-07-0546.", "ArticleIdList": ["10.1158/1535-7163.MCT-07-0546", "18089720"]}, {"Citation": "Labrinidis A., Hay S., Liapis V., Ponomarev V., Findlay D.M., Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin. Cancer Res. 2009;15:3451\u20133461. doi: 10.1158/1078-0432.CCR-08-1616.", "ArticleIdList": ["10.1158/1078-0432.CCR-08-1616", "PMC5568249", "19401351"]}, {"Citation": "Ory B., Heymann M.F., Kamijo A., Gouin F., Heymann D., Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 2005;104:2522\u20132529. doi: 10.1002/cncr.21530.", "ArticleIdList": ["10.1002/cncr.21530", "16270320"]}, {"Citation": "Conry R.M., Rodriguez M.G., Pressey J.G. Zoledronic acid in metastatic osteosarcoma: Encouraging progression free survival in four consecutive patients. Clin. Sarcoma Res. 2016;6:6. doi: 10.1186/s13569-016-0046-2.", "ArticleIdList": ["10.1186/s13569-016-0046-2", "PMC4848872", "27127605"]}, {"Citation": "Chen Y., Zhang H., Zhou H.J., Ji W., Min W. Mitochondrial redox signaling and tumor progression. Cancers. 2016;8:40. doi: 10.3390/cancers8040040.", "ArticleIdList": ["10.3390/cancers8040040", "PMC4846849", "27023612"]}, {"Citation": "Ibrahim T., Liverani C., Mercatali L., Sacanna E., Zanoni M., Fabbri F., Zoli W., Amadori D. Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines. Int. J. Oncol. 2013;42:1263\u20131270. doi: 10.3892/ijo.2013.1809.", "ArticleIdList": ["10.3892/ijo.2013.1809", "23403907"]}, {"Citation": "Ozturk O.H., Bozcuk H., Burgucu D., Ekinci D., Ozdogan M., Akca S., Yildiz M. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: Preliminary results of an in vitro study. Cell Biol. Int. 2007;31:1069\u20131071. doi: 10.1016/j.cellbi.2007.02.004.", "ArticleIdList": ["10.1016/j.cellbi.2007.02.004", "17418595"]}, {"Citation": "Koto K., Murata H., Kimura S., Horie N., Matsui T., Nishigaki Y., Ryu K., Sakabe T., Itoi M., Ashihara E., et al. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol. Rep. 2010;24:233\u2013239.", "ArticleIdList": ["20514467"]}, {"Citation": "Kashyap D., Tuli H.S., Sharma A.K. Ursolic acid (UA): A metabolite with promising therapeutic potential. Life Sci. 2016;146:201\u2013213. doi: 10.1016/j.lfs.2016.01.017.", "ArticleIdList": ["10.1016/j.lfs.2016.01.017", "26775565"]}, {"Citation": "Chuang W.L., Lin P.Y., Lin H.C., Chen Y.L. The apoptotic effect of ursolic acid on SK-Hep-1 cells is regulated by the PI3K/Akt, p38 and JNK MAPK signaling pathways. Molecules. 2016;21:460. doi: 10.3390/molecules21040460.", "ArticleIdList": ["10.3390/molecules21040460", "PMC6274268", "27104510"]}, {"Citation": "Lin L., Baehrecke E.H. Autophagy, cell death, and cancer. Mol. Cell. Oncol. 2015;2:e985913. doi: 10.4161/23723556.2014.985913.", "ArticleIdList": ["10.4161/23723556.2014.985913", "PMC4905302", "27308466"]}, {"Citation": "Yang Z., Klionsky D.J. Eaten alive: A history of macroautophagy. Nat. Cell Biol. 2010;12:814\u2013822. doi: 10.1038/ncb0910-814.", "ArticleIdList": ["10.1038/ncb0910-814", "PMC3616322", "20811353"]}, {"Citation": "White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer. 2012;12:401\u2013410. doi: 10.1038/nrc3262.", "ArticleIdList": ["10.1038/nrc3262", "PMC3664381", "22534666"]}, {"Citation": "Lin J.F., Lin Y.C., Lin Y.H., Tsai T.F., Chou K.Y., Chen H.E., Hwang T.I. Zoledronic acid induces autophagic cell death in human prostate cancer cells. J. Urol. 2011;185:1490\u20131496. doi: 10.1016/j.juro.2010.11.045.", "ArticleIdList": ["10.1016/j.juro.2010.11.045", "21334668"]}, {"Citation": "Wang I.T., Chou S.C., Lin Y.C. Zoledronic acid induces apoptosis and autophagy in cervical cancer cells. Tumour Biol. 2014;35:11913\u201311920. doi: 10.1007/s13277-014-2460-5.", "ArticleIdList": ["10.1007/s13277-014-2460-5", "25142231"]}, {"Citation": "Ge X.Y., Yang L.Q., Jiang Y., Yang W.W., Fu J., Li S.L. Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83. PLoS ONE. 2014;9:e101207. doi: 10.1371/journal.pone.0101207.", "ArticleIdList": ["10.1371/journal.pone.0101207", "PMC4071064", "24963720"]}, {"Citation": "Schumacker P.T. Reactive oxygen species in cancer: A dance with the devil. Cancer Cell. 2015;27:156\u2013157. doi: 10.1016/j.ccell.2015.01.007.", "ArticleIdList": ["10.1016/j.ccell.2015.01.007", "25670075"]}, {"Citation": "Yang Y., Jiang M., Hu J., Lv X., Yu L., Qian X., Liu B. Enhancement of radiation effects by ursolic acid in bgc-823 human adenocarcinoma gastric cancer cell line. PLoS ONE. 2015;10:e0133169. doi: 10.1371/journal.pone.0133169.", "ArticleIdList": ["10.1371/journal.pone.0133169", "PMC4503735", "26177078"]}, {"Citation": "De Colli M., Zara S., di Giacomo V., Patruno A., Marconi G.D., Gallorini M., Zizzari V.L., Tete G., Cataldi A. Nitric oxide-mediated cytotoxic effect induced by zoledronic acid treatment on human gingival fibroblasts. Clin. Oral Investig. 2015;19:1269\u20131277. doi: 10.1007/s00784-014-1344-9.", "ArticleIdList": ["10.1007/s00784-014-1344-9", "25352469"]}, {"Citation": "Bruzzese F., Pucci B., Milone M.R., Ciardiello C., Franco R., Chianese M.I., Rocco M., Di Gennaro E., Leone A., Luciano A., et al. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ros and modulating mevalonate and p38-MAPK pathways. Cell Death Dis. 2013;4:e878. doi: 10.1038/cddis.2013.406.", "ArticleIdList": ["10.1038/cddis.2013.406", "PMC3920938", "24157872"]}, {"Citation": "Koto K., Murata H., Kimura S., Sawai Y., Horie N., Matsui T., Ryu K., Ashihara E., Maekawa T., Kubo T., et al. Zoledronic acid significantly enhances radiationinduced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling. Int. J. Oncol. 2013;42:525\u2013534.", "ArticleIdList": ["23242142"]}], "ReferenceList": []}], "History": [{"Year": "2016", "Month": "10", "Day": "25"}, {"Year": "2016", "Month": "11", "Day": "16"}, {"Year": "2016", "Month": "11", "Day": "25"}, {"Year": "2016", "Month": "12", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "12", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "5", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "11", "Day": "30"}], "PublicationStatus": "epublish", "ArticleIdList": ["27916903", "PMC6274426", "10.3390/molecules21121640", "molecules21121640"]}}], "PubmedBookArticle": []}